- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 787KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 44KB)
Bevacizumab – March 2021
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Mvasi®
Last updated
2 July 2021